Chemotherapy for patients with gastric cancer after complete resection: A network meta-analysis

Table 1 Characteristics of randomized trials included in the network meta-analysis

Trial	Year	Postoperative chemotherapy regimens	Sample size		Overall mortality		Follow-up (mo)	Jadad score
			Chemotherapy group	Control group	Chemotherapy group	Control group
Lawton et al[20]	1981	FU + BCNU	13	12	11/13	10/12	60	2
Stablein et al[21]	1982	FU + MCCNU	71	71	29/71	40/71	48	3
Higgins et al[22]	1983	FU + MCCNU	156	156	121/156	117/156	36	3
Nakajima et al[23]	1984	FM + Ara-c	128	124	11/128	17/124	60	3
Engstrom et al[24]	1985	FU + MCCNU	91	89	57/91	51/89	24	3
Schlag et al[25]	1987	FU + BCNU	42	53	21/42	28/53	72	2
Bonfanti et al[26]	1988	FU + MCCNU	75	69	63/75	56/69	84	4
Coombes et al[27]	1990	FMA	131	148	101/133	123/148	68	3
Estape et al[28]	1991	MMC	33	37	16/33	31/37	120	2
Krook et al[29]	1991	FA	61	64	41/61	43/64	60	3
Kim et al[30]	1992	MMC + FU	77	94	54/77	71/94	60	2
Grau et al[31]	1993	MMC	68	66	40/68	49/66	105	2
Hallissey et al[32]	1994	FMA	138	145	101/138	110/145	60	3
Macdonald et al[33]	1995	FMA	93	100	59/93	68/100	114	2
Lise et al[34]	1995	FMA	155	159	88/155	99/159	78	3
Tsavaris et al[35]	1996	FMA	42	42	27/42	34/42	60	3
Cirera et al[36]	1999	MMC + Tegafur	76	76	33/ 76	44/72	37	3
Nakajima et al[37]	1999	MMC + FU + UFT	288	285	41/288	49/285	72	3
Neri et al[38]	2001	Epirubicin + FU	69	68	48/69	59/68	60	2
Bajetta et al[39]	2002	FU + Adriamycin etoposide + cisplatin	137	137	66/137	71/137	66	2
Nashimoto et al[40]	2003	MMC + FU + Ara C	128	124	11/128	23/124	69	2
Popiela et al[41]	2004	FAM	53	52	42/53	47/52	120	2
Chipponi et al[42]	2004	Cisplatin + FU	101	104	62/101	63/104	60	2
Bouché et al[43]	2005	Cisplatin + FU	127	133	68/127	77/133	97.8	3
Nitti et al[44]	2006	FU + Adriamycin + methotrexate + LV	103	103	54/103	49/103	60	3
Nitti et al[44]	2006	FU + Epirubicin + methotrexate + LV	91	100	63/91	64/100	60	3
De Vita et al[45]	2007	FU + Epirubicin + LV + etoposide	112	113	58/112	64/113	60	2
Nakajima et al[46]	2007	Uracil-Tegafur	95	95	18/95	30/95	60	4
Di Costanzo et al[47]	2008	FU + Epirubicin + cisplatin + LV	130	128	69/130	70/128	60	3
Miyashiro et al[48]	2011	Cisplatin + FU	132	132	50/132	52/132	60	4
Sasako et al[49]	2011	S-1	529	530	149/529	206/530	60	4

FU: Fluorouracil; MCCNU: Methyl-CCNU; MMC: Mitomycin c; LV: Leucovorin; Ara-c: Cytarabine; CDHP: 5-Chloro-2,4-dihydropyrimidine; Oxo: Potassium oxonate; FM: FU + MMC; FMA: FU + MMC + adriamycin; S-1: Tegafur + CDHP + Oxo.